Determinants for In Vivo Antitumor Effect of Angiogenesis Inhibitor SU5416 Formulated in PEGylated Emulsion
この論文をさがす
説明
Angiogenesis, the sprouting of capillaries from preexisting ones, is essential for the sustained growth of solid tumors. In this study, we used SU5416, a hydrophobic molecule with potent tyrosine kinase inhibitor of type 2 receptor for vascular endothelial growth factor (VEGF), as PEGylated emulsion (SU5416-PE), and evaluated the antitumor potency of this formulation in Lewis lung cancer (LLC), Colon-26 (C26), and B16BL6 melanoma (B16) tumor-bearing mice. Intravenous injection of SU5416-PE into tumor-bearing mice significantly suppressed the growth of C26 and B16 tumors, but had no effect on the growth of LLC tumors. MTT assay revealed that SU5416 inhibited the proliferation of human umbilical vein endothelial cells in a concentration-dependent manner but did not show such an inhibitory effect on all types of tumor cells examined, demonstrating the specificity of SU5416 for endothelial cells. Considering that VEGF levels within C26 and B16 tumors were found to be about 10-fold and 20-fold higher than that in LLC tumors, respectively, it was suggested that SU5416-PE would inhibit angiogenesis in certain types of tumor tissue such as C26 and B16 where VEGF plays a major role for promoting angiogenesis, leading to the suppression of in vivo tumor growth.
収録刊行物
-
- Journal of Pharmaceutical Sciences
-
Journal of Pharmaceutical Sciences 103 2464-2469, 2014-08-01
Elsevier BV
- Tweet
キーワード
- Male
- Vascular Endothelial Growth Factor A
- Mice, Inbred BALB C
- Indoles
- Neovascularization, Pathologic
- Angiogenesis Inhibitors
- Antineoplastic Agents
- Cell Line
- Polyethylene Glycols
- Mice, Inbred C57BL
- Mice
- Cell Line, Tumor
- Neoplasms
- Animals
- Humans
- Emulsions
- Pyrroles
- Endothelium, Vascular
- Pharmaceutical Vehicles
- Protein Kinase Inhibitors